Stefano Navarro: Partial GPVI Downregulation Shows Promise for Safer Antithrombotic Therapy
Stefano Navarro, Postdoctoral Researcher at Rudolf Virchow Center of University of Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Signal Transduction and Targeted Therapy, adding:
“What if antiplatelet therapy does not always need to completely block a platelet receptor?
This is the idea we explored in our new article in Signal Transduction and Targeted Therapy.
Instead of fully blocking or downregulating the collagen/fibrin (fibrinogen) receptor Glycoprotein (GP) VI, we asked whether its surface expression could be ‘tuned down’ to an intermediate level.
By partially downregulating GPVI, we generated a low-density GPVI phenotype (GPVILO) in which the adhesive function of the receptor was largely preserved, while its intracellular signaling was selectively dampened.
This uncoupling of adhesion from signaling was sufficient to protect from thrombosis and thrombo-inflammation, while preserving hemostasis in our experimental models.
Many thanks to all co-authors and collaborators who contributed to this work, and especially to Bernhard Nieswandt for his guidance throughout the project.”
Title: Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
Authors: Stefano Navarro, Sarah Beck, Sabrina I. Bonfiglio, Ernesto J. Cuenca-Zamora, Lukas J. Weiß, Marijke Kuijpers, Johan Heemskerk, David Stegner, Bernhard Nieswandt
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 6, 2026, 22:43Alessandra Bosch: Pediatric GTH Opens with Regional Experts Convening on Pediatric Hemostasis and Thrombosis
-
Oct 6, 2026, 22:39Managing Thrombotic Risk in Pregnancy: How the Lab May Help – Sysmex Europe
-
Oct 6, 2026, 22:33Ahmet Davut Aksu: A Multi-Objective Approach to Enhance Fibrinolysis, Selectivity, and Inhibition Resistance
-
Oct 6, 2026, 22:29Muhammad Abubakar: New Study on Iron Biology to Be Presented at ASH 2026 and Published in Blood
-
Oct 6, 2026, 22:24David McIntosh: Calling On Decision-Makers to Prioritize Donors and Clinical Access During IPAW 2026
-
Oct 6, 2026, 22:21Zoltan Nagy: With All Eyes on Optogenetics Today, What Can It Do in Megakaryocytes and Platelets?
-
Oct 6, 2026, 22:13Khalid A. Fakhro: Sidra Medicine Hosts RAPID 2026 Advancing Diagnostics and Treatments for Inborn Errors of Immunity
-
Oct 6, 2026, 22:04Denis Oduor: Preparedness for Postpartum Haemorrhage Must Include Preparedness for Blood
-
Oct 6, 2026, 21:57Farhad Moradpour: Health Equity and Public Health – What Drives Anemia Disparities in Ethnic Minority Populations?